期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌治疗靶向基因研究进展及临床分子病理检测 被引量：3

Research progress of genes in lung cancer target therapy and clinical molecular pathological detection
暂未订购
导出
摘要 以表皮生长因子受体(EGFR)、间变淋巴瘤激酶(ALK)基因融合变异等为治疗靶标的肺癌分子靶向治疗取得了长足进步。文章介绍了与EGFR酪氨酸激酶抑制剂(EGFR-TKI)和ALK基因融合变异抑制剂克唑替尼(Crizotinib)治疗用药相关的EGFR、K-RAS、BRAF、C-MET、EML4-ALK、ROS1等肺癌治疗靶向基因的作用原理,并详细阐述了上述基因分子病理检测的注意事项,包括对检测标本的要求、检测方法的选择和基因检测质量控制的要求。 Considerable progress has been made in lung cancer therapy targeted on epidermal growth factor receptor （EGFR） mutation and anaplastic lymphoma kinase （ALK） infusion. The mechanism of genes in lung cancer target therapy, such as EGFR, K-RAS, BRAF, C-MET, EMIA-ALK, ROS1 and their relationship with EGFR tyrosine kinase inhibitor （EGFR-TKI） and ALK gene infusion inhibitor are introduced. Meanwhile, important requirements in gene detection are elaborated, including the requirements for specimens, choice of methods and quality control in gene detection of lung cancer.
作者 张杰
机构地区 上海交通大学附属胸科医院病理科
出处 《上海交通大学学报（医学版）》 CAS CSCD 北大核心 2013年第10期1315-1322,共8页 Journal of Shanghai Jiao tong University:Medical Science
关键词 肺癌 靶向治疗 表皮生长因子受体 间变淋巴瘤激酶 分子病理 lung cancer target therapy epidermal growth factor receptor anaplastic lymphoma kinase molecular pathology
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献60

  • 1Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer epidemiology, risk factors, treatment, and survivorship [J]. Mayo Clin Proc, 2008, 83 (5) : 584 - 594.
  • 2Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors [J]. Nat Rev Cancer, 2005, 5 (5) : 341 - 354.
  • 3Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network [J]. Nat Rev Mol Cell Bioi, 2001,2(2): 127 -137.
  • 4Toyooka S, Yatabe Y, Tokumo M, et al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung[J]. Int J Cancer, 2006, 118 (6) : 1588 - 1590.
  • 5Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer[J]. Clin Cancer Res, 2008, 14(9) : 6092 - 6096.
  • 6Miller VA. Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer [J]. J Clin Oncol, 2004, 22 (6): 1103 -1109.
  • 7Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma [J]. Am J Surg Pathol, 2005,29(5): 633 -639.
  • 8张杰,吴洁,高慧,朱蕾,邵晋晨,时梅萍,韩宝惠.肺癌表皮生长因子受体基因突变和扩增与临床病理相关性研究[J].中华病理学杂志,2011,40(10):675-678. 被引量：12
  • 9Sueoka-Aragane N, Imai K, Komiya K, et al. Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1 [J]. Cancer Sci, 2008, 99(6): 1180 -1187.
  • 10Sasaki H, Endo K, Takada M, et al. EGFR polymorphism of the kinase domain in Japanese lung cancer[J]. J Surg Res, 2008, 148 (2) : 260 - 263.

二级参考文献68

  • 1高霞,刁路明,李恒,夏东,凌长明,刘铭球.非小细胞肺癌中肝细胞生长因子受体蛋白表达及其与肿瘤细胞增殖、血管生成的关系[J].武汉大学学报（医学版）,2005,26(3):273-275. 被引量：5
  • 2Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and poten tial for therapeutic inhibition [J]. Cytokine Growth Factor Rev, 2002,13(1) :41-59.
  • 3RosarioM, BirchmeierW. How tO make tubes: signaling by the Met receptor tyrosine kinase [J]. Trends Cell Biol, 2003,13: 328-35.
  • 4Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK/ ATF and cyclinD1 [J]. Oncogene, 2002,21(7):1000-1008.
  • 5Paumelle R, Tulasne D, Kherrouche Z, et al. Hepatocyte growth Factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF MEK-ERK signaling pathway [J]. Oncogene, 2002,21 (15) : 2309-2319.
  • 6Ichimura E, Maeshima A, Nakajima T, et al. Expression of c- met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance [J]. Jpn J Cancer Res, 1996,87(10):1063-1069.
  • 7Siegfried JM, Weissfeld LA, Singh-Kaw P, et al. Association of immunoreaetive hepatocyte growth factor with poor survival in rer, cctable non-small cell lung cancer [J]. Cancer Res, 1997, 57(3) :133-439.
  • 8Dietmaier W, Hartmann A, Wallinger S, et al. Multiple mutation analyses in single tumor ceils with improved whole genome amplification [J]. Am J Pathol, 1999,154 : 83-95.
  • 9Beau-Failer M, Ruppert AM, Voegeli AC et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort [J]. J Tbo rac Oneol, 2008,3(4) :331-339.
  • 10Engelman JA, Zejnullahu K, Mitsudomi T,et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J]. Science, 2007,316(5827) : 1039-1043.

共引文献171

同被引文献18

引证文献3

二级引证文献8

上海交通大学学报（医学版）
2013年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部